4 citations
,
March 2007 in “British Journal of Dermatology” Gefitinib therapy can cause unusual hair growth on the nose.
June 2011 in “Oncology times” Dr. Mario Lacouture recommends preventive and specific treatments for skin side effects caused by EGFR inhibitors to improve patients' quality of life.
10 citations
,
January 2023 in “SAGE Open Medical Case Reports” Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.
18 citations
,
December 2017 in “Medicine” Adding celecoxib to chemotherapy improves survival and quality of life for gastric cancer patients with positive COX-2.
2 citations
,
April 2023 in “Expert Review of Clinical Immunology” Baricitinib is effective as a treatment for severe hair loss.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
113 citations
,
May 2002 in “PubMed” Overexpressing COX-2 in mice skin reduces skin tumor development.
March 2025 in “NATIONS UNIVERSITY INTERNATIONAL JOURNAL OF MULTI-DISCIPLINARY STUDIES” Baricitinib effectively improved skin and hair conditions in a patient with alopecia areata and atopic dermatitis.
9 citations
,
October 2021 in “International Journal of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.
21 citations
,
October 2022 in “International Journal of Molecular Sciences” Quercitrin may help treat Alzheimer's by boosting brain cell signaling without causing tumors.
January 2026 in “Dermatology Reports” Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.
2 citations
,
January 1990 in “Leukemia & Lymphoma” The combination of mitoxantrone, etoposide, and prednisolone is effective for treating relapsed lymphoma with manageable side effects.
6 citations
,
March 2023 in “Frontiers in Cellular and Infection Microbiology” Golvatinib shows promise as a treatment for Omicron in elderly patients.
12 citations
,
May 2023 in “EMBO reports” High mTORC1 activity slows hair growth and causes it to lose color.
Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.
March 2025 in “SKIN The Journal of Cutaneous Medicine”
10 citations
,
July 2021 in “Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin” LRIG1 is linked to better survival in Merkel cell carcinoma.
October 2025 in “Actualización en Medicina de Familia” New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.
Minoxidil effectively promotes hair growth in seborrheic alopecia.
June 2025 in “British Journal of Dermatology” Tofacitinib was more effective than methotrexate for treating alopecia areata.
1 citations
,
January 2023 in “Bioscience Journal” Sorafenib and Platycladus orientalis leaf extract together effectively suppress cervical cancer cell growth.
9 citations
,
May 2013 in “JAMA Dermatology” A woman's hair turned white after taking a cancer drug called dasatinib.
February 2006 in “PubMed” Docetaxel slightly extends prostate cancer survival but has significant side effects and high cost.
February 2026 in “Indian Journal of Dermatology” Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.
August 2013 in “Nature Reviews Drug Discovery” New treatments may restore cancer-blocking proteins, slow prostate cancer, identify drug targets, and potentially regrow hair.
2 citations
,
December 2024 in “Journal of the American Academy of Dermatology” Low-dose oral minoxidil combined with topical minoxidil improves hair density in breast cancer patients but may cause excess hair growth.
July 2024 in “Journal of Investigative Dermatology” ATR04-484 ointment shows promise for treating skin issues from cancer therapies.
March 2022 in “International Journal of Trichology” Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.
2 citations
,
December 2022 in “PNAS nexus” SCD-153 shows promise as an effective topical treatment for alopecia areata.
20 citations
,
May 2011 in “Journal of Clinical Investigation” The study created a mouse model to mimic degenerative diseases for testing tissue repair and new therapies.